Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss

    Maryanne M. Senna, Oh Sang Kwon, Bianca Maria Piraccini, Rodney Sinclair, Susan Ball, Yuxin Ding, Yunfei Chen, Yves Dutronc, Brett King
    Image of study
    TLDR Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
    The document presents an analysis of two randomized, double-blinded, placebo-controlled trials (BRAVE-AA1 and BRAVE-AA2) evaluating the efficacy of Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, in promoting eyebrow and eyelash regrowth in patients with severe alopecia areata (AA) who did not achieve a Severity of Alopecia Tool (SALT) score ≤20 (20% or less scalp hair loss) at Week 36. The results showed that in patients with a SALT score >20 at Week 36, treatment with baricitinib 4 mg resulted in achievement rates of 19.8% for ClinRo EB (0, 1) and 22.6% for ClinRo EL (0, 1) versus 3.5-3.9% with placebo (P ≤ .001). For baricitinib 2 mg, the rate of ClinRo EB (0, 1) was 10.4% (P ≤ .01 versus placebo 3.5%) and ClinRo EL was 9.4% (P = .051, versus placebo 3.9%). Therefore, baricitinib therapy resulted in clinically meaningful improvement in hair growth for eyebrows and eyelashes in those with SALT score >20 at Week 36.
    View this study on →


    6 / results